The human GLP-1 analogs liraglutide and semaglutide: Absence of histopathological effects on the pancreas in nonhuman primates

Diabetes

Volumn 63, Issue 7, 2014, Pages 2486-2497

  Gotfredsen, Carsten F ^a   Mølck, Anne Marie ^a   Thorup, Inger ^a   Berg Nyborg, Niels C ^a   Salanti, Zaki ^a   Knudsen, Lotte Bjerre ^a   Larsen, Marianne O ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LIRAGLUTIDE; SEMAGLUTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GERMINAL CENTER; HISTOPATHOLOGY; MACACA FASCICULARIS; MALE; NONHUMAN; ORGAN WEIGHT; PANCREAS; PANCREAS ISLET; PANCREAS WEIGHT; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; BODY WEIGHT; DRUG EVALUATION, PRECLINICAL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; MACACA FASCICULARIS; MALE; ORGAN SIZE; PANCREAS; PRIMATES;

EID: 84903166001     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1087     Document Type: Article

References (50)

1. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007;113:546-593 (Pubitemid 46365961)
2. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism 2013;17:819-837
3. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest 2012;122:388-402
4. Ali S, Lamont BJ, Charron MJ, Drucker DJ. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 2011;121:1917-1929
5. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24 (Pubitemid 29505281)
6. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619 (Pubitemid 44833446)
7. Aaboe K, Knop FK, Vilsbøll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010;12:323-333
8. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011;96:1695-1702
9. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of antiexenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012;14:546-554
10. Rosenstock J, Balas B, Charbonnel B, et al.; T-emerge 2 Study Group. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care 2013;36:498-504
11. 1c and body weight in patients with type 2 diabetes. Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany. Diabetologia 2012;55(Suppl.):S7
12. World Health Organization. WHO guidelines on the quality, safety, and efficacy of biotherapeutic products prepared by recombinant DNA technology. Available from http://www.who.int/biologicals/WHO-rDNA-2nd-public-consultation- 28-June-2013.pdf. Accessed 14 Oct 2013
13. Nyborg NC, Mølck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-1249
14. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009;58:2148-2161
15. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012;61:1250-1262
16. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
17. Ruehl-Fehlert C, Kittel B, Morawietz G, et al.; RITA Group; NACAD Group. Revised guides for organ sampling and trimming in rats and mice - part 1. Exp Toxicol Pathol 2003;55:91-106 (Pubitemid 37309758)
18. Crissman JW, Goodman DG, Hildebrandt PK, et al. Best practices guideline: toxicologic histopathology. Toxicol Pathol 2004;32:126-131 (Pubitemid 38250001)
19. Bock T, Svenstrup K, Pakkenberg B, Buschard K. Unbiased estimation of total beta-cell number and mean beta-cell volume in rodent pancreas. APMIS 1999;107:791-799 (Pubitemid 29434453)
20. Gundersen HJ. The smooth fractionator. J Microsc 2002;207:191-210
21. Larsen MO, Wilken M, Gotfredsen CF, Carr RD, Svendsen O, Rolin B. Mild streptozotocin diabetes in the Göttingen minipig. A novel model of moderate insulin deficiency and diabetes. Am J Physiol Endocrinol Metab 2002;282: E1342-E1351 (Pubitemid 34654704)
22. Novo Nordisk: Liraglutide (injection) for the treatment of patients with type 2 diabetes. NDA 22-341. Available from http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicand metabolicdrugsadvisorycommittee/ucm148659.pdf. Accessed 11 July 2013
23. Kharouta M, Miller K, Kim A, et al. No mantle formation in rodent islets - the prototype of islet revisited. Diabetes Res Clin Pract 2009;85:252-257
24. Boyce JT, Boyce RW, Gundersen HJ. Choice of morphometric methods and consequences in the regulatory environment. Toxicol Pathol 2010;38: 1128-1133
25. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58: 1604-1615
26. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010; 53:153-159
27. Williams AJK, Thrower SL, Sequeiros IM, et al. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab 2012;97:E2109-E2113
28. Cuntz U, Frank G, Lehnert P, Fichter M. Interrelationships between the size of the pancreas and the weight of patients with eating disorders. Int J Eat Disord 2000;27:297-303 (Pubitemid 30160007)
29. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62:2178-2180
30. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013;62:3316-3323
31. Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger RH. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 1982;31:694-700 (Pubitemid 12095166)
32. Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia 1983;24:366-371 (Pubitemid 13092224)
33. Street CN, Lakey JR, Shapiro AM, et al. Islet graft assessment in the Edmonton Protocol: implications for predicting long-term clinical outcome. Diabetes 2004;53:3107-3114 (Pubitemid 39564485)
34. Wieczorek G, Pospischil A, Perentes E. A comparative immunohistochemical study of pancreatic islets in laboratory animals (rats, dogs, minipigs, nonhuman primates). Exp Toxicol Pathol 1998;50:151-172 (Pubitemid 28293898)
35. Kim A, Miller K, Jo J, Kilimnik G, Wojcik P, Hara M. Islet architecture: A comparative study. Islets 2009;1:129-136
36. Steiner DJ, Kim A, Miller K, Hara M. Pancreatic islet plasticity: interspecies comparison of islet architecture and composition. Islets 2010;2:135-145
37. Bock T, Pakkenberg B, Buschard K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 2003;111:1117-1124 (Pubitemid 38091251)
38. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007;56:8-15
39. Cummings BP, Stanhope KL, Graham JL, et al. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 2010;59:2653-2661
40. Vrang N, Jelsing J, Simonsen L, et al. The effects of 13 weeks of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF-rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 2012;303:E253-264
41. Aston-Mourney K, Subramanian SL, Zraika S, et al. One year of sitagliptin treatment protects against islet amyloid-associated b-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. Am J Physiol Endocrinol Metab 2013;305:E475-E484
42. Hummer B. FDA surveillance of adverse drug effects (Abstract). NIH Pancreatitis, Diabetes, Pancreatic Cancer Workshop, Bethesda, MD, 12-13 June 2013:8-9
43. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013;154:127-139
44. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor - or not? Endocrinology 2013;154:4-8
45. Michel MC, Wieland T, Tsujimoto G. How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol 2009;379:385-388
46. Pradidarcheep W, Stallen J, Labruyère WT, Dabhoiwala NF, Michel MC, Lamers WH. Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 2009;379:397-402
47. Hamdani N, van der Velden J. Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 2009;379:403-407
48. Gore AC. Editorial: antibody validation requirements for articles published in endocrinology. Endocrinology 2013;154:579-580
49. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007;48:736-743 (Pubitemid 47604973)
50. Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52:1073-1078